Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD5991 + Selumetinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD5991 | AZD-5991|AZD 5991 | MCL1 Inhibitor 18 | AZD5991 binds to and inhibits Mcl1, potentially resulting in increased tumor cell apoptosis and decreased tumor growth (Cancer Res July 1 2017 (77) (13 Supplement) DDT01-02, PMID: 32204955). | |
Selumetinib | Koselugo | AZD6244|ARRY-142886 | MEK inhibitor (Pan) 26 MEK1 Inhibitor 26 MEK2 Inhibitor 24 | Koselugo (selumetinib) inhibits mitogen-activated protein kinase kinases (MEK or MAPK/ERK kinases) 1 and 2, which may prevent the activation of MEK1/2-dependent effector proteins and transcription factors, reducing cellular proliferation in various cancers (PMID: 27467210). Koselugo (selumetinib) is FDA approved for use in pediatric patients of 2 years or older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61L | acute myeloid leukemia | sensitive | AZD5991 + Selumetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Koselugo (selumetinib) and AZD5991 synergistically inhibited viability of an acute myeloid leukemia cell line harboring NRAS Q61L in culture (PMID: 38456804). | 38456804 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|